1247001-60-0

Basic information

• Product Name: 1H-Indazole, 6-bromo-1-(phenylmethyl)-
• CAS NO: 1247001-60-0
• Molecular Weight: 287.159
• Mol File: 1247001-60-0.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 1H-Indazole, 6-bromo-1-(phenylmethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indazole, 6-bromo-1-(phenylmethyl)-(1247001-60-0)
• EPA Substance Registry System: 1H-Indazole, 6-bromo-1-(phenylmethyl)-(1247001-60-0)

Safety Data

• Hazardous Substances Data: 1247001-60-0(Hazardous Substances Data)

Usage

Chemical Family

1H-Indazole, 6-bromo-1-(phenylmethyl)belongs to the indazole family.

Derivative

It is a derivative of indazole with a bromo substituent at the 6th position.

Substitution

A phenylmethyl group is attached to the nitrogen atom.

Pharmacological Properties

1H-Indazole, 6-bromo-1-(phenylmethyl)has potential pharmacological properties.

Medicinal Chemistry

It has potential applications in medicinal chemistry and drug development.

Building Block

It may be used as a building block for the synthesis of various biologically active molecules and pharmaceuticals.

Ongoing Research

Research on the biological activities of 1H-Indazole, 6-bromo-1-(phenylmethyl)is ongoing.

Therapeutic Uses

It is being investigated for its potential therapeutic uses in the treatment of various diseases.

Upstream product

• 79762-54-2 6-bromo-1H-indazole 
• 100-44-7 benzyl chloride 

Downstream Products

• 1338805-99-4 (1R,2S)-(E)-2-(3-(4-((dimethylamino)methyl)styryl)-1H-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one hydrochloride 
• 1247002-44-3 (1R,2S)-5'-methoxy-2-(3-(4-(morpholinomethyl)styryl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one hydrochloride 
• 1247001-87-1 (1R,2S)-1'-benzyl-2-(1-benzyl-1H-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one 
• 1247001-72-4 (1R,2S)-2-(1-benzyl-1H-indazol-6-yl)-1'-methylspiro[cyclopropane-1,3'-indolin]-2'-one 
• 1247001-75-7 (1R,2S)-2-(1-benzyl-1H-indazol-6-yl)-5'-methoxy-1'-methylspiro[cyclopropane-1,3'-indolin]-2'-one 
• 1338806-32-8 (1R,2S)-(E)-2-(3-(4-(piperazin-1-yl)styryl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one 2,2,2-trifluoroacetate 
• 1338806-73-7 (1R,2S)-(E)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5‘-methoxyspiro[cyclopropane-1,3’-indolin]-2-one 
• 1338806-37-3 (1R,2S)-(E)-2-(3-(4-((dimethylamino)methyl)styryl)-1H-indazol-6-yl)-1'-methylspiro[cyclopropane-1,3'-indolin]-2'-one 2,2,2-trifluoroacetate 
• 1338806-09-9 (1R,2S)-(E)-2-(3-(4-(pyrrolidin-1-ylmethyl)styryl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one 2,2,2-trifluoroacetate 
• 1338806-36-2 (1R,2S)-(E)-2-(3-(4-(((R)-3-fluoropyrrolidin-1-yl)methyl)styryl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one 2,2,2-trifluoroacetate 
• 1338806-06-6 (1R,2S)-(E)-2-(3-(4-(piperidin-1-ylmethyl)styryl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one 2,2,2-trifluoroacetate 
• 1338806-07-7 (1R,2S)-(E)-5'-methoxy-2-(3-(4-(piperidin-1-ylmethyl)styryl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one 2,2,2-trifluoroacetate 
• 1338806-35-1 (1R,2S)-(E)-5'-methoxy-1'-methyl-2-(3-(4-(morpholinomethyl)styryl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one hydrochloride 
• 1616420-30-4 (1R,2S)-(E)-2-(3-(4-(cis-2,6-dimethylmorpholinomethyl)styryl)-1H-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one fumarate 

Relevant articles and documents

Design, synthesis, and evaluation of novel pyridone derivatives as potent BRD4 inhibitors for the potential treatment of prostate cancer

Since androgen receptor (AR) can bind to BRD4 protein and this binding can be blocked by BRD4 inhibitors, targeting BRD4 has emerged as a promising approach for the treatment of prostate cancer (PC). Herein, we designed and synthesized a series of 5-(1-benzyl-1H-indazol-6-yl)-4-ethoxy-1-methylpyridin-2(1H)-one derivatives as novel BRD4 inhibitors for prostate cancer. Among them, compound 13 displayed the most robust BRD4 inhibitory activity with an IC50 value of 18 nM. Furthermore, 13 showed potent anti-proliferative activity against enzalutamide-resistant 22RV1 cells. The mechanism of action studies demonstrated that 13 induced cell apoptosis by regulating Bcl-2/Bax proteins and activating caspase-3 signaling pathway. In addition, the c-Myc level was significantly reduced in 22RV1 cells on the western blot assay. These findings collectively suggested that compound 13 might find potential use for the treatment of prostate cancer.